Biosimilar Interchangeability Checker
Check FDA-Approved Interchangeable Biosimilars
The Purple Book is the FDA's official database for biologic drugs and biosimilars. Search for your drug to see if it has FDA-approved interchangeable biosimilars.
The Purple Book isn’t a book you can hold. It’s a live, searchable database run by the U.S. Food and Drug Administration (FDA) that tells you which biological drugs are approved, which ones are biosimilars, and which ones can actually be swapped out at the pharmacy like generic pills. If you’re a pharmacist, a doctor, or even a patient trying to understand why your insulin or arthritis drug suddenly has a different name but the same price, this is the resource that explains it all.
What Exactly Is the Purple Book?
Launched in 2012 as part of the Biologics Price Competition and Innovation Act (BPCIA), the Purple Book started as two separate lists-one for drugs handled by the Center for Drug Evaluation and Research (CDER), another for those under the Center for Biologics Evaluation and Research (CBER). But in 2020, the FDA merged them into one clean, searchable system. Today, it’s the go-to source for anyone needing to know if a biological product is approved, if it’s a biosimilar, or if it’s interchangeable.
Think of it like a digital catalog, but instead of listing books, it lists complex medicines made from living cells-things like insulin, rheumatoid arthritis treatments, cancer drugs, and vaccines. Each entry includes the brand name, the generic name, when it was approved, and whether it’s a reference product, a biosimilar, or an interchangeable product.
Biosimilars vs. Interchangeable Products: The Difference That Matters
Here’s where things get tricky. Not all biosimilars are the same. All interchangeable products are biosimilars, but not all biosimilars can be swapped at the pharmacy.
A biosimilar is a biological product that’s extremely similar to an already-approved reference product. The FDA says there are no clinically meaningful differences in safety, purity, or potency. That means if you’re on Humira, and your doctor switches you to a biosimilar version, it should work just as well. But here’s the catch: a biosimilar alone doesn’t let a pharmacist automatically substitute it for the brand name drug.
An interchangeable product goes further. To earn that label, the FDA requires extra proof: switching back and forth between the biosimilar and the original product doesn’t increase risk or reduce effectiveness. That means if a patient uses the brand drug for a month, then switches to the biosimilar for a month, then switches back, their body responds the same way every time. No drop in results. No spike in side effects.
That’s why interchangeability matters. It’s not about being better. It’s about being predictable. The FDA makes it clear: an interchangeable designation doesn’t mean the product is safer or more effective-it just means you can switch between them without worrying about unintended consequences.
How the Purple Book Shows You What’s What
The Purple Book doesn’t just list products. It groups them smartly. When you search for Humira, you’ll see its original listing-and underneath it, all the biosimilars and interchangeable versions that have been approved to match it. Each one has a matching color on its product card so you can instantly tell which ones are linked.
Each product card also shows icons for how the drug is delivered-autoinjector, pre-filled syringe, vial-so pharmacists and patients know what to expect. The date of approval, whether it’s covered by exclusivity, and its regulatory path (351(a), 351(k) biosimilar, or 351(k) interchangeable) are all clearly labeled.
For example, if you search for “insulin glargine,” you’ll see multiple entries. One might say “Lantus (reference),” and below it, two biosimilars, and one marked “interchangeable.” That one can be swapped without asking the doctor-depending on your state’s rules.
Why State Laws Change Everything
Even if the FDA says a biosimilar is interchangeable, that doesn’t mean every pharmacy will automatically swap it. Each state has its own rules.
As of 2023, 47 states and Puerto Rico allow pharmacists to substitute an interchangeable biosimilar without contacting the prescriber. But in those states, some still require the pharmacist to notify the doctor, document the swap, or tell the patient. A few states still require explicit permission from the prescriber every time.
This creates a patchwork. A patient in New York might get an interchangeable biosimilar without knowing. A patient in California might get the same drug, but only after the pharmacist calls the doctor. And in states that don’t allow substitution at all, even an FDA-approved interchangeable product stays on the shelf.
That’s why the Purple Book doesn’t tell you what you can get-it tells you what’s approved. The rest? That’s up to your state pharmacy board.
What’s Approved So Far?
As of late 2023, only seven biosimilars had earned the interchangeable designation from the FDA. That might sound low, but it’s growing fast.
Two of them are insulin products-critical for people with diabetes who need consistent, affordable options. Three treat inflammatory conditions like rheumatoid arthritis and Crohn’s disease. Two are for eye conditions in patients with diabetic retinopathy.
These aren’t experimental. They’re all based on well-established reference products with decades of safety data. The FDA didn’t approve them lightly. Each one went through multiple clinical trials showing that switching back and forth didn’t hurt patients.
Companies are now filing more applications. More interchangeable biosimilars are expected in the next 12-18 months, especially for popular drugs like adalimumab and etanercept.
What the Purple Book Doesn’t Tell You
The Purple Book is a regulatory tool, not a clinical guide. It won’t tell you which drug is cheaper. It won’t tell you if your insurance covers it. It won’t explain side effects in plain language.
It also doesn’t distinguish between “unbranded biologics” and interchangeable biosimilars. The FDA calls unbranded biologics “equivalent” to the brand name, but they’re not interchangeable under federal law. That’s a gray area that even some pharmacists get confused about.
And while the database is searchable and updated daily, it doesn’t include products that are pending approval or under review. If you’re looking for a biosimilar that’s not listed yet, it’s not because the FDA hid it-it’s because it hasn’t been approved.
Who Uses the Purple Book-and Why?
Pharmacists rely on it daily to decide if they can substitute a drug. Prescribers use it to understand what options are available when writing new prescriptions. Patients can use it to check if their medication has a cheaper, FDA-approved alternative.
Insurance companies use it to update their formularies. Policymakers use it to shape state laws. Researchers use it to track how many biosimilars are entering the market.
It’s not marketing. It’s not opinion. It’s the official, factual record of what the FDA has approved-and that’s rare in healthcare.
Where to Find It
The Purple Book is free, online, and updated daily. Go to fda.gov, search for “Purple Book,” and you’ll land on the official page. You can search by brand name, generic name, or manufacturer. You can filter by product type-insulin, autoimmune, oncology-and see only the interchangeable products.
The FDA even has a short video walkthrough that shows you how to use it. No login. No fee. No subscription. Just clear, accurate data.
And unlike older versions, it’s now a single, unified database. No more flipping between two separate lists. No more confusion.
What’s Next?
The FDA is working on clearer labeling rules for biosimilars and interchangeable products. That means future product cards will be even easier to read. More companies are investing in switching studies to earn interchangeability status. As costs keep falling, more patients will gain access to these drugs.
But the real shift isn’t just in the science. It’s in the system. The Purple Book is helping turn biological drugs from exclusive, high-cost products into ones that can be competed with, substituted, and made affordable.
That’s the goal of the BPCIA. And the Purple Book? It’s the tool making it real.
Is the Purple Book the same as the Orange Book?
No. The Orange Book lists approved generic chemical drugs and their patent status. The Purple Book does the same thing-but for biological products, including biosimilars and interchangeable products. They’re two separate systems for two different kinds of medicines.
Can a pharmacist substitute a biosimilar without telling me?
Only if it’s an FDA-approved interchangeable product AND your state allows substitution without prescriber permission. Even then, some states require the pharmacist to notify your doctor or document the swap. Always ask your pharmacist if substitution happened.
Are interchangeable biosimilars safer than regular biosimilars?
No. The FDA says interchangeability doesn’t mean a product is safer or more effective. It just means switching between it and the original drug won’t cause unexpected changes in safety or effectiveness. Both types are held to the same high standard for similarity.
Why aren’t there more interchangeable biosimilars on the market?
Because proving interchangeability takes more time and money. Companies need to run additional clinical studies showing that switching back and forth between the biosimilar and the brand drug doesn’t change outcomes. That’s harder and costlier than proving basic biosimilarity. Many companies are working on it, but it’s a slower process.
Can I use the Purple Book to find cheaper alternatives to my biologic?
Yes. Search your brand-name biologic in the Purple Book. If you see one or more biosimilars listed under it, those are FDA-approved alternatives. If one is marked “interchangeable,” it may be automatically substitutable in your state. Talk to your pharmacist or doctor to see if switching is right for you.
Dylan Patrick
March 14, 2026 AT 22:05This Purple Book thing is wild. I’m a pharmacist and I use it daily. No more guessing if I can swap insulin brands. It’s like having a cheat code for biologics.
Used to be a nightmare-patients would show up with a new script and we’d spend 20 minutes checking databases. Now? Search. Click. Done.
And yeah, interchangeability? Huge. It’s not about being ‘better.’ It’s about being predictable. That’s the whole point.
My favorite part? Seeing patients save hundreds a month without losing efficacy. That’s healthcare working.
Still, state laws are a mess. One day I’m swapping automatically, next day I’m calling a doctor in Nebraska because they still think biosimilars are ‘experimental.’
It’s 2024. We’ve had FDA-approved biosimilars for over a decade. Time to stop treating them like aliens.
The FDA’s not the problem. It’s the bureaucracy.
Also-side note-why do people still confuse this with the Orange Book? Like, come on.
Kathy Leslie
March 16, 2026 AT 06:31Just read this after my dad switched to a biosimilar for his RA. He didn’t even notice the change. Just cheaper. And now I know why.
Thanks for explaining it so clearly. I’m sharing this with my whole family.
Amisha Patel
March 17, 2026 AT 23:05Interesting. In India we don’t have this system yet. But biosimilars are everywhere here. Mostly for insulin and TNF inhibitors.
Do you think the Purple Book model could work here?
Would love to see something like this adopted. No more confusion in rural clinics.
Elsa Rodriguez
March 19, 2026 AT 00:19OH MY GOD I CAN’T BELIEVE THIS IS REAL
THE FDA ACTUALLY MADE A DATABASE THAT’S USEFUL
LIKE A REAL ONE
NOT A JOKING MESS LIKE THE REST OF GOVERNMENT WEBSITES
MY THERAPIST SWITCHED ME TO AN INTERCHANGEABLE BIOSIMILAR LAST MONTH AND I THOUGHT I WAS GETTING SCAMMED
TURNED OUT I WAS JUST GETTING SAVED
WHY DOESN’T EVERYTHING WORK LIKE THIS
WHY ISN’T MEDICARE LIKE THIS
WHY ISN’T THE IRS LIKE THIS
WHY DO WE EVEN HAVE A HEALTHCARE SYSTEM
WHY
WHY
WHY
Serena Petrie
March 19, 2026 AT 22:09So… it’s just a list?
Buddy Nataatmadja
March 21, 2026 AT 21:23As someone from Indonesia, I’m amazed at how transparent this is.
In my country, biosimilars exist but no one knows if they’re interchangeable or not. Pharmacists just guess.
This system? It’s a blueprint.
Maybe one day we’ll have something like this. Hope so.
mir yasir
March 22, 2026 AT 10:12The notion that the FDA can independently validate interchangeability without full-scale phase IV trials is scientifically dubious. The biological complexity of monoclonal antibodies demands more rigorous post-marketing surveillance than a mere database can provide.
While commendable in intent, this initiative may inadvertently encourage substitution without sufficient clinical evidence of immunogenicity equivalence.
One must question the regulatory precedent being set here.
Stephanie Paluch
March 24, 2026 AT 09:55OMG I just looked up my insulin and there’s an INTERCHANGEABLE one!! 🤯💉
I’ve been paying $500/month for 5 years
My pharmacist said she could switch me
But I was scared
Now I know it’s legit
Thank you for this 🙏❤️
tynece roberts
March 25, 2026 AT 04:53so i was reading this and like… i thought the purple book was a real book?? like a physical thing??
like i imagined this big dusty volume with purple cover and like… a librarian in a tweed jacket handing it to you
then i clicked the link and it was just… a website
like… why did they call it a book??
why not just… the biosimilar registry??
why the mystery??
also i just found out my arthritis med has a cheaper version
and i’m crying
not because i’m sad
because i’m so mad i didn’t know sooner
why is this not on tv??
why is this not in every pharmacy flyer??
why is no one talking about this??
Hugh Breen
March 25, 2026 AT 07:14This is one of the most underappreciated wins in modern healthcare.
👏👏👏
Look-biosimilars are the future. Affordable, safe, effective.
And the Purple Book? It’s the backbone.
Pharmacists in the UK are begging for something like this. We’re stuck with paper lists and outdated guidelines.
Why can’t the NHS just adopt this? It’s free. It’s public. It’s flawless.
Also-interchangeable insulin? That’s life-changing for diabetics.
Someone needs to make a TikTok about this.
Like… right now.
Byron Boror
March 25, 2026 AT 11:55Why is the FDA even involved in this? This is just another way to give foreign drug makers a foot in the door.
Let’s stick with American-made biologics. Full stop.
These biosimilars? They’re not the same. They’re just cheaper knockoffs.
And now they’re letting pharmacists swap them without telling patients?
That’s not freedom. That’s betrayal.
My dad’s on Humira. I wouldn’t let some foreign-made version touch him.
Make America Biologic Again.
Lorna Brown
March 25, 2026 AT 14:56What’s fascinating here isn’t just the database-it’s the philosophical shift.
The Purple Book doesn’t just catalog drugs. It redefines trust in medicine.
For decades, biologicals were treated like sacred, untouchable artifacts.
Now? We’re treating them like products-complex, yes-but products nonetheless.
That’s radical.
It means we’re finally accepting that science can be standardized.
That safety isn’t about brand names.
That cost and efficacy can coexist.
And that patients deserve to know, without jargon, what they’re getting.
This isn’t just regulatory.
This is cultural.